Alexion Presents Promising Data on Ultomiris and Soliris at 2025 AAN Annual Meeting

On March 27, 2025, Alexion, AstraZeneca Rare Disease, announced it will present 21 abstracts—including three oral presentations—at the upcoming American Academy of Neurology (AAN) Annual Meeting in San Diego (April 5–9, 2025). The presentations focus on long-term safety and efficacy data for **Ultomiris (ravulizumab)** and **Soliris (eculizumab)** in treating **neuromyelitis optica spectrum disorder (NMOSD)** and **generalised myasthenia gravis (gMG)**.

Highlights include:

- **CHAMPION-NMOSD trial** data showing that **no relapses occurred** among Ultomiris-treated patients during a median follow-up of over 170 weeks.
- Real-world data from Japan confirming Soliris' effectiveness in gMG patients, with sustained benefits across severity levels and for those switching to Ultomiris.
- Registry-based evidence demonstrating decreased corticosteroid use and fewer hospitalisations among gMG patients on C5 inhibitors.
- Biomarker research suggesting that glial fibrillary acidic protein (GFAP) and neurofilament light chain (NfL) levels may provide insights into disease activity in NMOSD, though not predictive of relapse risk.
- Early findings from a smartphone-based study (ME&MGopen™) show potential for digital tracking of daily symptom impact in gMG patients.
- Ongoing trials, including a Phase III study of Ultomiris in paediatric gMG and the PREVAIL trial of the investigational drug **gefurulimab**, were also featured.
- Project ASPIRE results shed light on health disparities in gMG, emphasizing the need for equitable access to care for people of color.

These findings further support the safety and long-term benefit of Ultomiris and Soliris, reinforcing Alexion's leadership in rare neurological disease care and its commitment to advancing treatment equity and patient-focused innovation.